Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial
Writing Group for the Women's Health Initiative … - Jama, 2002 - jamanetwork.com
ContextDespite decades of accumulated observational evidence, the balance of risks and
benefits for hormone use in healthy postmenopausal women remains uncertain. ObjectiveTo
assess the major health benefits and risks of the most commonly used combined hormone
preparation in the United States. DesignEstrogen plus progestin component of the Women's
Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5
years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at …
benefits for hormone use in healthy postmenopausal women remains uncertain. ObjectiveTo
assess the major health benefits and risks of the most commonly used combined hormone
preparation in the United States. DesignEstrogen plus progestin component of the Women's
Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5
years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at …
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
ContextDespite decades of accumulated observational evidence, the balance of risks and
benefits for hormone use in healthy postmenopausal women remains uncertain. ObjectiveTo
assess the major health benefits and risks of the most commonly used combined hormone
preparation in the United States. DesignEstrogen plus progestin component of the Women's
Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5
years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at …
benefits for hormone use in healthy postmenopausal women remains uncertain. ObjectiveTo
assess the major health benefits and risks of the most commonly used combined hormone
preparation in the United States. DesignEstrogen plus progestin component of the Women's
Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5
years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at …